Civil Law and Comparative Emerging Healthcare Regulation Trends in the USA

1. Introduction

Healthcare regulation in the United States is undergoing significant transformation due to artificial intelligence, telemedicine, health-data privacy, pharmaceutical innovation, rising healthcare costs, medical malpractice disputes, and the growing role of private healthcare organizations.

Healthcare regulation determines how medical services are delivered, how providers are licensed, how patient information is protected, how medicines and medical devices are approved, and how healthcare institutions are held accountable for negligence, discrimination, fraud, and unsafe practices.

Unlike countries with a predominantly centralized healthcare system, the United States uses a complex combination of federal and state law. Federal legislation regulates areas such as Medicare, Medicaid, medical-device safety, health-information privacy, and certain insurance practices. States retain substantial authority over medical licensing, professional negligence, hospital regulation, insurance, and public health.

The principal emerging trends include:

Regulation of artificial intelligence in diagnosis and treatment.

Expansion of telehealth and interstate medical practice.

Stronger protections for patient information and electronic health records.

Regulation of automated insurance decisions and healthcare algorithms.

Pharmaceutical pricing, drug approval, and access to treatment.

Reproductive healthcare, patient autonomy, and emergency treatment obligations.

Healthcare cybersecurity and the protection of critical infrastructure.

Accountability for hospitals, healthcare corporations, and medical professionals.

The central legal challenge is to promote innovation and access to healthcare while protecting patient safety, informed consent, privacy, equality, and accountability.

2. Legal framework governing healthcare in the United States

A. Federal healthcare legislation

The principal federal statutes and regulatory frameworks include:

HIPAA is not a universal privacy law covering every health-related app or consumer service. Whether it applies depends on the entity, information, and activity involved. Other federal and state privacy laws may apply when HIPAA does not.

B. State healthcare regulation

States generally regulate:

Medical licensing and professional discipline.

Medical malpractice and informed consent.

Hospital and clinic licensing.

Pharmacy practice and many aspects of professional prescribing.

Insurance products and specified healthcare billing practices.

Public-health measures and emergency response.

Telemedicine practice within their jurisdictions.

State laws differ substantially. A healthcare organization operating nationally may therefore need to comply with multiple licensing, privacy, consent, insurance, and professional-practice regimes.

C. Administrative agencies

Several federal agencies play central roles in healthcare regulation:

Department of Health and Human Services (HHS): oversees major federal healthcare programs and policy functions.

Centers for Medicare & Medicaid Services (CMS): administers Medicare, Medicaid, and related programs.

Food and Drug Administration (FDA): regulates drugs, biological products, medical devices, and other products within its statutory authority.

Office for Civil Rights (OCR): enforces HIPAA and certain civil-rights requirements within its authority.

Federal Trade Commission (FTC): addresses specified unfair or deceptive practices, including certain health-data and digital-health practices outside or alongside other regulatory frameworks.

The division of responsibility can produce overlapping oversight, especially where digital health businesses combine medical services, software, advertising, insurance, and consumer data.

3. Emerging healthcare regulation trends

A. Artificial intelligence and clinical decision-making

Artificial intelligence is increasingly used to interpret medical images, identify patient risks, recommend treatment, summarize clinical records, and support administrative decisions.

The legal challenge is determining when an AI system is merely an assistive tool and when it performs a regulated medical function. FDA oversight may apply to software that meets the statutory definition of a medical device, while state medical boards regulate licensed practitioners and the practice of medicine.

In May 2026, the Federation of State Medical Boards announced a workgroup to develop recommendations on regulating AI in medical practice, with particular attention to clinical tools operating with limited physician supervision. This reflects ongoing regulatory development rather than a single nationwide AI licensing regime.

production.fsmb.org

+1

Emerging issues include:

Whether physicians adequately supervise AI-assisted diagnosis.

Whether patients should be informed when AI materially influences their care.

Whether developers and providers are responsible for algorithmic errors.

How to document the clinical reasoning behind an AI-supported decision.

Whether biased training data produces unlawful discrimination.

Illustration: If a hospital's AI triage system repeatedly underestimates the severity of symptoms in a particular patient population, liability may depend on the applicable standard of care, the hospital's implementation and monitoring, professional responsibilities, and the causal connection to patient injury.

B. Telemedicine and interstate medical practice

Telehealth enables remote consultations, diagnosis, monitoring, and behavioral healthcare. It can improve access in rural areas and for patients with mobility or transportation barriers, but it raises questions about licensure, prescribing, privacy, reimbursement, and clinical suitability.

Federal Medicare telehealth flexibilities have been extended through December 31, 2027 for many non-behavioral and behavioral healthcare services, although the rules differ by service and provider. Certain behavioral-health telehealth flexibilities are permanent.

telehealth.hhs.gov

Important legal issues include:

Whether a physician must hold a license in the state where the patient is located.

Whether the remote examination is sufficient to meet the standard of care.

Whether a controlled substance can lawfully be prescribed without an in-person visit.

Whether the platform meets applicable privacy and security requirements.

Whether the service qualifies for insurance reimbursement.

The likely direction is continued integration of telehealth into ordinary healthcare delivery, accompanied by state-specific professional regulation and evolving reimbursement requirements.

C. Health-data privacy and cybersecurity

Electronic health records, connected devices, remote consultations, and health applications produce large amounts of sensitive personal information.

HIPAA's Privacy, Security, and Breach Notification Rules apply to covered entities and business associates within their scope. However, health information collected by consumer applications may fall outside HIPAA, depending on the organization and circumstances. Other federal and state privacy laws can apply.

telehealth.hhs.gov

+1

Emerging issues include:

Unauthorized disclosure of medical records.

Cyberattacks on hospitals and healthcare suppliers.

Secondary use of patient data to train AI models.

Tracking technologies embedded in healthcare websites.

Commercial collection of reproductive, genetic, and location data.

Data access, correction, and interoperability rights.

Healthcare organizations increasingly need documented access controls, vendor-risk assessments, incident-response procedures, data-retention policies, and legally appropriate patient authorizations.

D. Medical-device and digital-health regulation

Digital therapeutics, wearable sensors, remote-monitoring systems, and AI-enabled diagnostic software blur the distinction between ordinary consumer products and regulated medical devices.

FDA regulation depends on the product's intended use, functionality, risk, and applicable statutory classification. A wellness product is not automatically a medical device, but a product intended to diagnose or treat disease may fall within the FDA's regulatory authority.

The FDA's 2026 guidance on certain low-risk wellness products clarifies how some wearable technologies that estimate physiological measurements may qualify for the general-wellness policy, subject to stated conditions.

Every CRS Report

This distinction matters for manufacturers, healthcare providers, patients, and insurers because it affects marketing claims, evidence requirements, safety controls, and potential liability.

E. Pharmaceutical regulation and patient access

Pharmaceutical regulation involves drug approval, manufacturing standards, labeling, adverse-event reporting, prescription practices, and post-market monitoring.

Emerging legal debates concern:

Expedited approval pathways and confirmatory evidence.

Generic and biosimilar competition.

Drug pricing and insurance coverage.

Direct-to-consumer pharmaceutical advertising.

Liability for defective products and inadequate warnings.

Access to innovative treatments for rare or serious diseases.

Federal pre-emption is especially important. A state-law claim against a pharmaceutical manufacturer may be restricted where Congress or an authorized federal regulatory framework has displaced the relevant state requirement. The outcome depends on the statute, the type of product, and the specific claim.

F. Insurance coverage and automated utilization management

Insurers increasingly use software and predictive analytics to assess claims, determine eligibility, and support prior-authorization decisions.

These systems may affect access to medically necessary treatment. Legal questions include whether a denial complies with the insurance contract, applicable federal and state requirements, procedural review obligations, and prohibitions on discrimination.

A computer-generated denial is not automatically unlawful, but automation does not eliminate the insurer's legal responsibilities. Evidence of inaccurate data, failure to consider individual circumstances, or noncompliance with governing coverage standards may be relevant in litigation.

G. Reproductive healthcare and emergency treatment

Reproductive healthcare regulation has become particularly complex because federal law, state restrictions, constitutional doctrine, and emergency-treatment requirements can interact.

In Moyle v. United States and Idaho v. United States (2024), the Supreme Court allowed emergency abortions to continue in Idaho in circumstances covered by the relevant federal district-court order while the litigation proceeded. The Court did not issue a final nationwide resolution of every conflict between EMTALA and state abortion restrictions.

Healthcare providers must therefore examine the applicable federal and state law, the patient's medical circumstances, and the current status of relevant judicial orders.

H. Disability rights and healthcare equality

Healthcare providers may face liability for discrimination based on disability, including failures to provide reasonable modifications or effective communication where required.

Algorithmic systems may introduce additional risks if they use disability-related data or proxies in ways that disadvantage patients. Legal analysis must distinguish between clinically justified criteria and unlawful discrimination.

The ADA, Section 504 of the Rehabilitation Act, and other applicable federal and state laws may provide relevant protections, depending on the institution, funding, service, and facts.

I. Hospital accountability and healthcare administration

Healthcare institutions are increasingly responsible for managing complex networks of clinicians, contractors, software vendors, and affiliated facilities.

Legal exposure may arise from negligent credentialing, inadequate supervision, unsafe protocols, improper delegation, billing fraud, or failures to maintain appropriate cybersecurity safeguards.

A hospital's responsibility depends on the particular legal theory and jurisdiction. Direct negligence, vicarious liability, statutory violations, and contractual obligations are distinct routes to accountability.

4. Leading American healthcare regulation cases

The following ten decisions illustrate the interaction between federal regulatory power, state authority, patient access, pharmaceutical regulation, insurance, and professional accountability.

Case 1. National Federation of Independent Business v. Sebelius (2012)

Citation: 567 U.S. 519 (2012).

Facts: The case challenged provisions of the Affordable Care Act, including the individual health-insurance requirement and the expansion of Medicaid.

Decision: The Supreme Court upheld the individual shared-responsibility payment under Congress's taxing power, while limiting the federal government's ability to compel states to expand Medicaid by threatening existing Medicaid funding.

Legal principle: Congress possesses substantial authority over national healthcare policy, but its constitutional powers have limits. Federal conditions attached to state funding must comply with constitutional restrictions.

Emerging significance: The decision remains fundamental to healthcare federalism, insurance reform, and disputes over the relationship between federal healthcare objectives and state administration.

Case 2. King v. Burwell (2015)

Citation: 576 U.S. 473 (2015).

Facts: The dispute concerned whether tax credits under the Affordable Care Act were available to eligible individuals purchasing insurance through federally established exchanges.

Decision: The Supreme Court held that the statutory tax credits were available to qualifying individuals purchasing insurance through both state and federally established exchanges.

Legal principle: Statutory provisions must be interpreted in the context of the legislation as a whole, particularly where a provision is central to the operation of a complex regulatory scheme.

Emerging significance: The decision illustrates how statutory interpretation can affect insurance affordability, market stability, and the practical reach of federal healthcare legislation.

Case 3. Loper Bright Enterprises v. Raimondo (2024)

Citation: 603 U.S. 369 (2024).

Facts: Although the case arose under federal fisheries legislation rather than healthcare law, it concerned the degree of deference courts should give to federal agencies interpreting ambiguous statutes.

Decision: The Supreme Court overruled Chevron U.S.A. Inc. v. Natural Resources Defense Council, Inc. and held that courts must exercise independent judgment when interpreting statutes. Agency interpretations may remain persuasive, but statutory ambiguity alone does not require Chevron deference.

Legal principle: Courts, not agencies, have the ultimate responsibility to determine the meaning of federal statutes within the judicial role.

Emerging significance for healthcare: The decision has implications for challenges to FDA, HHS, CMS, and other healthcare-agency rules. Courts may independently assess whether an agency's interpretation falls within its statutory authority.

It does not abolish all agency discretion or invalidate healthcare regulations automatically.

Case 4. West Virginia v. Environmental Protection Agency (2022)

Citation: 597 U.S. 697 (2022).

Facts: The case involved the EPA's authority to adopt a broad regulatory approach to carbon emissions from power plants.

Decision: The Supreme Court applied the major questions doctrine and held that the agency lacked clear congressional authorization for the particular regulatory approach at issue.

Legal principle: Agencies generally require clear statutory authorization for regulatory actions of extraordinary economic and political significance.

Emerging significance for healthcare: Although not a healthcare case, the doctrine can be relevant when agencies assert expansive powers over pharmaceutical pricing, insurance markets, public-health regulation, or healthcare technologies.

Its application depends on the statute and the particular regulatory action being challenged.

Case 5. Wyeth v. Levine (2009)

Citation: 555 U.S. 555 (2009).

Facts: A patient suffered severe injury after receiving a pharmaceutical drug through an intravenous administration method. She alleged that the manufacturer had failed to provide an adequate warning about the risk.

Decision: The Supreme Court held that the patient's state-law failure-to-warn claim was not pre-empted on the facts presented.

Legal principle: Federal drug approval does not automatically eliminate state-law failure-to-warn claims. The pre-emption analysis depends on the applicable federal requirements and whether the manufacturer could have complied with both federal law and the relevant state-law duty.

Emerging significance: The decision is important for pharmaceutical product liability, drug labeling, adverse-event information, and the allocation of responsibility between manufacturers and regulators.

Case 6. Riegel v. Medtronic, Inc. (2008)

Citation: 552 U.S. 312 (2008).

Facts: A patient suffered serious complications involving a medical device that had undergone FDA premarket approval. The patient's representatives brought state-law product liability claims.

Decision: The Supreme Court held that the Medical Device Amendments pre-empted the state requirements at issue because they imposed requirements different from or additional to the federal requirements applicable to the approved device.

Legal principle: Express federal pre-emption can restrict state-law claims concerning medical devices subject to particular FDA approval requirements.

Emerging significance: The decision is central to disputes involving medical-device safety, device manufacturers, and the boundary between federal regulation and state tort law.

It should be distinguished from cases involving devices subject to different regulatory pathways.

Case 7. Bruesewitz v. Wyeth LLC (2011)

Citation: 562 U.S. 223 (2011).

Facts: Parents alleged that a vaccine caused their child to develop a serious medical condition and pursued a design-defect claim.

Decision: The Supreme Court held that the National Childhood Vaccine Injury Act pre-empted the design-defect claim against the vaccine manufacturer.

Legal principle: Congress may establish a specialized compensation and liability framework for products where uniform national rules are considered important to public health.

Emerging significance: The decision illustrates the interaction between vaccine safety, compensation for injury, manufacturer liability, and national immunization policy.

Case 8. Gonzales v. Oregon (2006)

Citation: 546 U.S. 243 (2006).

Facts: Oregon permitted physician-assisted dying under state law. The federal government attempted to use the Controlled Substances Act to restrict physicians who prescribed controlled substances in accordance with the state regime.

Decision: The Supreme Court rejected the federal government's interpretation of the statute as authority to prohibit the conduct at issue.

Legal principle: Federal agencies must act within the authority delegated by Congress. General statutory powers do not automatically confer authority to regulate every aspect of medical practice.

Emerging significance: The decision is important for understanding the boundary between federal drug-control regulation and state authority over medical practice, professional conduct, and healthcare policy.

Case 9. Moyle v. United States / Idaho v. United States (2024)

Citation: 603 U.S. 324 (2024).

Facts: The federal government argued that EMTALA required covered hospitals to provide emergency abortion care in certain circumstances, notwithstanding Idaho's abortion restrictions. Idaho disputed the scope of federal authority.

Decision: The Supreme Court dismissed the cases as improvidently granted and vacated its stay, allowing the relevant district-court injunction to remain effective while the litigation continued.

Legal principle: EMTALA imposes emergency screening and stabilization duties on covered hospitals, but the relationship between those duties and state abortion restrictions generated unresolved legal questions.

Emerging significance: The litigation demonstrates the difficulty of reconciling emergency medical treatment obligations with conflicting state and federal requirements.

The decision did not finally resolve the national scope of EMTALA's application to abortion care.

Case 10. National Institute of Family and Life Advocates v. Becerra (2018)

Citation: 585 U.S. 755 (2018).

Facts: California required certain licensed pregnancy-related centers to provide notices about state-sponsored reproductive services and required unlicensed centers to disclose their licensing status.

Decision: The Supreme Court held that the challenged notice requirements were subject to First Amendment scrutiny and found the provisions unconstitutional in the circumstances before it.

Legal principle: Healthcare regulation must respect constitutional protections for speech, including when the state regulates the communications of healthcare-related organizations.

Emerging significance: The case is relevant to reproductive-health regulation, mandated disclosures, professional speech, and the constitutional limits of state regulation of healthcare communications.

5. Comparative analysis: United States and other healthcare systems

The United States can be compared with the United Kingdom, Canada, and the European Union to understand alternative approaches to healthcare governance.

Comparative lessons

First, regulatory fragmentation: The United States has multiple layers of authority, which can produce uncertainty for healthcare providers operating across state lines. Canada also has divided jurisdiction, while the UK's regulatory arrangements differ among its constituent nations.

Second, patient privacy: HIPAA offers significant protection for specified health information, but it does not cover every health application or consumer technology. The scope of protection must be assessed under all applicable laws.

Third, AI accountability: Across these jurisdictions, existing medical-device rules, professional duties, privacy legislation, and negligence principles remain important. The development of AI-specific standards is an evolving process rather than a uniform global system.

Fourth, emergency treatment: The United States has a specific federal emergency-treatment statute, EMTALA. Other jurisdictions rely on different combinations of statutory duties, professional standards, and public healthcare obligations.

6. Future directions of American healthcare regulation

1. Risk-based AI governance

Regulators are likely to pay greater attention to the clinical risk of AI systems, the extent of human supervision, model performance, documentation, and post-deployment monitoring. State medical-board initiatives and FDA oversight will remain important, although their respective jurisdictions differ.

production.fsmb.org

+1

2. Stronger digital-health privacy

The growing use of consumer health applications and connected devices will continue to raise questions about consent, data sharing, secondary use, and security. Organizations will need to determine whether HIPAA, state privacy statutes, FTC requirements, or other laws apply to their activities.

3. Greater emphasis on interoperability

Healthcare providers increasingly need to exchange medical information across institutions and platforms. Regulation must balance efficient access to records against privacy, cybersecurity, and appropriate restrictions on disclosure.

4. Evolving telehealth standards

Telehealth will continue to raise questions about interstate licensing, prescribing, reimbursement, and clinical standards. Providers must distinguish permanent policies from temporary statutory extensions and state-specific requirements.

telehealth.hhs.gov

+1

5. More litigation over agency authority

Following Loper Bright, challenges to healthcare regulations may increasingly focus on the statutory basis for agency action. The major questions doctrine may also be relevant to claims of broad regulatory authority. Neither doctrine automatically invalidates agency regulations; the governing statute and the particular action remain decisive.

6. Cybersecurity as a patient-safety obligation

Healthcare cybersecurity failures can affect treatment availability, confidentiality, and continuity of care. Providers may face overlapping regulatory, contractual, and negligence-related consequences when inadequate safeguards contribute to harm.

7. Renewed attention to healthcare equality

Automated eligibility, insurance, and treatment systems may create new forms of discrimination. Regulators and courts will continue to assess how applicable civil-rights laws, professional obligations, and insurance requirements address those risks.

7. Conclusion

Emerging healthcare regulation in the United States reflects a continuing effort to balance medical innovation, patient autonomy, public health, constitutional rights, and institutional accountability.

The ten cases discussed illustrate different dimensions of this legal framework:

NFIB v. Sebelius and King v. Burwell address federal healthcare policy and insurance regulation.

Loper Bright and West Virginia v. EPA illuminate the limits of administrative authority.

Wyeth v. Levine, Riegel v. Medtronic, and Bruesewitz v. Wyeth demonstrate how federal law interacts with pharmaceutical and medical-device liability.

Gonzales v. Oregon addresses the boundary between federal drug regulation and state medical-practice authority.

Moyle and NIFLA v. Becerra illustrate conflicts involving emergency treatment, reproductive healthcare, and constitutional protections.

The broader direction of healthcare law is toward more sophisticated oversight of digital medicine, AI-supported decisions, patient data, and complex healthcare institutions. However, technological development does not displace established principles of informed consent, professional competence, patient safety, privacy, and lawful regulation.

The central legal objective remains ensuring that healthcare innovation operates within a framework that protects patients, preserves access to medically necessary treatment, and holds institutions accountable under the law.

Educational note: This overview is for academic purposes and is not legal advice. Healthcare regulation varies by state and may change through legislation, agency action, and subsequent judicial decisions.